The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world data on treatment of chromophobe renal cell carcinoma.
 
Dena Battle
Consulting or Advisory Role - Exelixis; Pfizer
Other Relationship - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Merck; Pfizer
 
Meghan Griffith
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; AstraZeneca; BMS; Genentech/Roche
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EMD Serono; EUSA Pharma; Exelixis; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Apogepha; Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Exelixis; Ipsen; Merck Sharp & Dohme; Novartis; Oncorena; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer